54 results about "Vector vaccine" patented technology

The invention belongs to the technical field of biology, and particularly relates to an immunogenic peptide fragment aiming at a human sphingosine 1-phosphate receptor 2 and application of the immunogenic peptide fragment. The amino acid sequence of the immunogenic peptide fragment is SEQ ID No.1. The immunogenic vector vaccine aiming at the human sphingosine 1-phosphate receptor 2 is prepared by coupling the immunogenic peptide fragment of the human sphingosine 1-phosphate receptor 2 and a vector, and the vector is Q beta-2aa bacteriophage virus-like particle protein. According to the invention, the preferentially designed immunogenic peptide fragment of the human sphingosine 1-phosphate receptor 2 is coupled with the Qbeta-2aa bacteriophage virus-like particle protein carrier to successfully prepare the carrier vaccine. The immunogenic vector vaccine can be used for preparing drugs for preventing and treating abdominal aortic aneurysm.

The invention relates to a genome large fragment deleted duck adenovirus B2 strain and application thereof, the duck adenovirus B2 strain is duck adenovirus B2 DAdV-B2 / delta ORF55-ORF19, and is preserved in China Center for Type Culture Collection on September 26, 2025, and the preservation number is CCTCC NO: V202568. Compared with the duck adenovirus B2 strain BGMH, the duck adenovirus B2 strain has a deletion region between ORF20 and ORF53 genes, and the duck adenovirus B2 strain is deleted by 7422 bp. According to the invention, the duck adenovirus B2 strain with the genome deleted in large fragment is found for the first time, and the deletion region of the virus is a good site for inserting an exogenous gene, so that the duck adenovirus B2 DAdV-B2 / delta ORF55-ORF19 can be used as a good virus vector to construct a recombinant virus, and the constructed recombinant virus can be stably inherited; the method can be applied to waterfowl novel recombinant virus vector vaccine research and development, waterfowl basic scientific research, gene virus vector delivery and the like, and has wide application prospect and value.

The present invention relates to an atomized inhalable vaccine formulation and a preparation method therefor. The formulation comprises an active ingredient and auxiliary materials. The active ingredient is an antigen protein-expressing recombinant human replication-defective adenovirus at a low concentration. The auxiliary materials include a buffer, a protectant, a stabilizer, a surfactant, and an osmotic pressure regulator. The atomized inhalable vaccine formulation of the present invention can retain the good stability of a human replication-defective adenovirus vector vaccine formulation.

The application relates to the technical field of biological medicine, and particularly discloses a fish rhabdovirus recombinant adenovirus vector vaccine and a preparation method and application thereof. The recombinant adenovirus vaccine carrying the M gene of the SCRV virus is prepared by using a replication-defective recombinant adenovirus vector, and the preparation method comprises the following steps: mandarin fish rhabdovirus M gene cloning, construction of a Pshuttle-CMV-ECMV vector with a target gene SCRV-M, obtaining of a SCRV-M recombinant adenovirus plasmid, screening of the SCRV-M recombinant adenovirus, and preparation of the SCRV-M recombinant adenovirus vaccine. The SCRV-M recombinant adenovirus vaccine prepared by the application can be used for immunoprophylaxis of SCRV virus infection in the juvenile fish stage through a soaking mode, the SCRV-M recombinant adenovirus vaccine has passed an animal safety test, and has a wide application prospect in the prevention and control of fish rhabdovirus.

The invention belongs to the technical field of biological medicine, and particularly relates to a rabies virus G protein carrier, a rabies virus vaccine and a preparation method and application of the rabies virus G protein carrier and the rabies virus vaccine. The rabies virus G protein vector pscAAV-G is obtained by inserting a coding gene of rabies virus G protein into a coding region between inverted terminal repetitive sequences at two ends of a double-chain adeno-associated virus vector, so that the problem of expression delay of single-chain AAV (ssAAV) is solved, and rapid and efficient expression of the rabies virus G protein is realized; furthermore, an endogenous nucleic acid adjuvant is embedded into a non-coding region of the pscAAV-G, so that the rabies virus G protein carrier pscAAV-G-Adj is prepared, and Th1 type immune response is remarkably improved. According to a rabies virus vaccine prepared by using the rabies virus G protein carrier, the antigen expression efficiency and immunogenicity of an AAV carrier vaccine are remarkably improved, long-acting protection of single inoculation is realized, and the defects that an existing rabies vaccine is short in immune cycle and needs to be inoculated for multiple times are overcome.

The invention relates to the field of aquaculture, in particular to a preparation method and application of a recombinant live vector vaccine for infectious hematopoietic necrosis of fish. In order to solve the problem of prevention and control of the infectious hematopoietic necrosis of the fish in the aquatic product industry, a replication-defective adenovirus type 5 is selected as a target gene expression vector to construct a recombinant adenovirus vector comprising a glycoprotein gene and a nucleoprotein gene of the infectious hematopoietic necrosis virus of the fish, and a recombinant virus is obtained; the safe and effective recombinant live vector vaccine for the infectious hematopoietic necrosis of the fish is created. According to the vaccine, immunization is carried out on fishes in a soaking or bait feeding mode, the total CPM of the fishes immunized by the vaccine is 6.67%, and the total CPM of the fishes in a non-immunized control group is 94.00%. In addition, the RPS of the vaccination group fish and the RPS of the empty vector control group fish are 92.90% and 9.22% respectively. The method is at a leading level in the field of fish biological medicines at present and has remarkable creativity.

The invention relates to the field of animal health. In particular, the present invention relates to a composition comprising a modified duck enteritis virus (DEV) comprising and capable of expressing a heterologous polynucleotide encoding an antigen of a chicken pathogen. In addition, the present invention relates to a composition comprising the modified DEV as a chicken vector vaccine and uses thereof. More particularly, the present invention relates to a vaccine composition against chicken pathogens comprising a modified DEV that does not exhibit or exhibits reduced pathogenicity in chicken.

The invention discloses a Brucella vaccine of recombinant adenovirus based on BP26 and IFNG and application, and belongs to the technical field of biological medicine. In order to develop a safe and effective brucella recombinant adenovirus vector vaccine, a brucella immunodominance antigen is designed through a genetic engineering technology, a recombinant adenovirus of an antigen-coupled molecular adjuvant IFN-gamma is constructed, and the constructed recombinant adenovirus is identified through PCR, WB, an electron microscope and the like. And the immune stimulation capability and the protective efficacy of the brucella recombinant adenovirus vector vaccine are evaluated by verifying the cellular immune response level and the humoral immune response level induced by the vaccine at a mouse level and the challenge protection efficiency, so that a foundation is laid for research and development of a brucella recombinant adenovirus candidate vaccine.

The invention provides an individualized mRNA composition, a carrier, an mRNA vaccine and application thereof, and belongs to the technical field of biological vaccines. Wherein the individualized mRNA composition comprises at least one neoantigen mRNA encoding a tumor neoantigen and at least one associated antigen mRNA encoding a tumor associated antigen. According to the present invention, the new antigen mRNA and the related antigen mRNA are combined to obtain the individualized vaccine material having the high tumor killing biological activity characteristic, such that the targeting killing ability of the tumor specific T cell is increased while the immune system activation progress is accelerated, the human body immune response can be improved, and the possible recurrence in the subsequent process can be prevented.

This invention provides a virus-like particle vaccine gE-eVLP for varicella-zoster virus, a recombinant adenovirus vector vaccine, an mRNA vaccine, and their preparation methods and applications, belonging to the field of vaccine technology. The nucleotide sequence of the virus-like particle vaccine gE-eVLP provided by this invention includes a signal peptide sequence, a truncated and / or mutated sequence of the gE domain without the original signal peptide, and an EGE motif; the recombinant adenovirus vector vaccine and mRNA vaccine contain gE-eVLP. This invention innovatively integrates EABR self-assembled particle technology into the VZV adenovirus vector vaccine and mRNA vaccine technology platform, and systematically evaluates the immunogenicity of three novel vaccines: Ad26-tPA-gE-eVLP, AdC68-tPA-gE-eVLP, and LNP-tPA-gE-eVLP, providing important experimental evidence for the development of a new generation of highly effective and safe VZV vaccines.

The present invention relates to the field of (vector) vaccines, and in particular to canine distemper virus (CDV) vectors comprising a heterologous nucleotide sequence encoding a porcine epidemic diarrhea virus (PEDV) antigen. The PEDV antigen is preferably the PEDV spike (S) protein. The viral vectors of the present invention can be used to produce immunogenic compositions or vaccines for intranasal immunization of sows and thereby protecting piglets suckled by such sows against clinical signs associated with PEDV infection.

The present invention relates to the field of animal health. Particularly, the present invention relates to a modified Duck Enteritis Virus (DEV). More particularly, the present invention relates to a modified DEV that shows no or reduced pathogenicity in chicken. Furthermore, the present invention relates to a composition, comprising the modified DEV of the invention as vector-vaccine for chicken, and the use thereof.

The invention belongs to the technical field of biological medicines, and particularly relates to a lactic acid bacteria live vector vaccine for preventing and treating brucellosis and a preparation method of the lactic acid bacteria live vector vaccine. The lactic acid bacteria live vector vaccine is obtained by transferring expression vectors for expressing Brucella omp19 protein and BvrR protein into lactic acid bacteria, and the lactic acid bacteria are lactobacillus cavings. The lactobacillus live vector vaccine for preventing and treating brucellosis is constructed by taking brucella omp19 protein and BvrR protein as immunogens and lactic acid bacteria as an antigen transfer vector, and the safety is good. After the vaccine is used for immunizing mice, the mice can obtain a higher antibody level, the duration is long, brucella infection is effectively inhibited, meanwhile, the production process of the vaccine is simplified, and the vaccine has a good application prospect.

The present invention discloses an immunogenic peptide segment for human β1-adrenergic receptor and its application, wherein the amino acid sequence of the immunogenic peptide segment is DEARRCYND, as shown in SEQ ID NO.1. The immunogenic vector vaccine for human β1-adrenergic receptor is prepared by coupling the above-mentioned immunogenic peptide segment of human β1-adrenergic receptor with a carrier, and the carrier is Qβ-2aa bacteriophage virus-like particle protein. The present invention successfully couples the preferentially designed immunogenic peptide segment of human β1-adrenergic receptor with the Qβ-2aa bacteriophage virus-like particle protein carrier to prepare a vector vaccine. The immunogenic vector vaccine can be used to prepare drugs for treating hypertension and improving cardiac remodeling after myocardial infarction.

The present invention regards a new recombinant HVT (rHVT) construct, useful as multivalent vector vaccine for poultry. The rHVT comprises 4 heterologous genes from poultry pathogens: the VP2 gene from IBDV, the F gene from NDV, and the gD and gI genes from ILTV. The VP2 and F genes are inserted in the Us genome region of the rHVT. The gD-gI genes are inserted in the UL genome region, between the UL54 and the LORF3 genes. The new rHVT-VP2-F-gD-gI proved to be genetically stable in vitro and in vivo, and expressed all inserted genes well. Also it was an effective vaccine against severe challenge infections with NDV, IBDV, and ILTV.

The present invention provides a bovine parainfluenza virus type 3 and bovine viral diarrhea virus bivalent adenovirus vector vaccine, prepared by cloning the BPIV3C F gene and the BVDV-1E2 gene into a replication-deficient human adenovirus type 5 vector. The BPIV3C F gene sequence is shown in SEQ ID No. 1, and the BVDV-1E2 gene sequence is shown in SEQ ID No. 2. The bivalent vaccine can stimulate the body to produce strong cellular and humoral immunity, with good immune efficacy and high safety.

This invention discloses a PRRSV NADC30 lineage vaccine, its preparation method, and its applications, belonging to the field of immunology technology. The recombinant chimpanzee adenovirus vector is obtained by introducing the encoding gene of GP35 fusion protein or M-GP5 fusion protein into an expression vector; wherein, the GP35 fusion protein is constructed by linking GP3 and GP5 proteins with a flexible linker peptide; the M-GP5 fusion protein is constructed by linking M and GP5 proteins with a flexible linker peptide. The PRRSV NADC30 lineage vaccine of this invention achieves protection against PRRSV infection by inducing antigen-specific antibodies, neutralizing antibodies, Th1-type cellular immune responses, and / or lymphocyte proliferation reactions. This invention provides a promising candidate antigen and a highly efficient vaccine platform for developing novel recombinant chimpanzee adenovirus vector vaccines against currently circulating NADC30-like strains.

The invention discloses a canine distemper virus envelope glycoprotein chimeric recombinant Newcastle disease virus as well as a construction method and application thereof, and belongs to the technical field of gene engineering. The CDV F extracellular region chimeric recombinant Newcastle disease virus rNDV-cF and the CDV H protein extracellular region chimeric recombinant Newcastle disease virus rNDV-cH are successfully constructed, the immunogenicity of the recombinant viruses is improved, the CDV F and the CDV H are better packaged to the surface of the NDV, and the recombinant viruses have good genetic stability. After the rNDV-cF and the rNDV-cH are inactivated, an adjuvant is supplemented for independent immunization or combined immunization of mice and dogs, the result shows that all immunization groups can induce the body to generate good humoral immune response, and the rNDV-cH inactivated vaccine and combined immunization have equivalent immune effect, and have good protective effect on dogs attacked by CDV virulent strains; and an important material basis is laid for research and development of novel canine distemper carrier vaccines.

The invention relates to the technical field of mucosal immunity and immunogenicity collaborative optimization, in particular to a preparation method of a mucosal immune type mycoplasma bovis live vector vaccine, attenuated mycoplasma bovis is used as a vector, an inducer X containing an FRET modified nucleic acid aptamer is combined with CRISPR-Cas12a for modification, a virulence gene is knocked out, and a mucosal targeting gene fused with CTB is inserted; carrying out deep codon optimization on the antigen gene, fusing the antigen gene with the glycosylation immunopotentiation peptide, and carrying out novel enzyme digestion connection to construct a recombinant vector; and intelligently fermenting in an improved culture medium, centrifuging, resuspending by using a special protective agent, and freeze-drying to obtain the vaccine. According to the preparation method, the mucous membrane targeting and immunogenicity of the vaccine are improved, and the production process is optimized; mucosal immunity can be quickly stimulated, various immune reactions are activated, the vaccine activity and quality are guaranteed, and the mycoplasmosis bovis is efficiently prevented.

The application discloses a single-chain circular DNA virus GyH1 recombinant polyepitope adenovirus vector vaccine and application thereof, and belongs to the technical field of vaccines.The antigen epitopes of GyH1 VP1, VP2 and VP3 proteins are screened through an online bioinformation analysis server, the antigen epitopes are connected by using a linker to construct a polyepitope vaccine GyMEV, and the nucleotide sequence of the GyMEV is obtained through reverse translation and codon optimization.The antigen polypeptide GyMEV nucleotide sequence is cloned into a plasmid vector pMD19-T through artificial synthesis, the GyMEV is directionally cloned into a linearized adenovirus vector by using seamless cloning technology to obtain a recombinant adenovirus plasmid rAd5-GyMEV, and the recombinant plasmid is transfected into HEK 293 cells to obtain the recombinant polyepitope adenovirus vector vaccine GyMEV.The results show that the GyMEV can more effectively stimulate the immune response of the body and has stronger protection.The vaccine also has the safety of a subunit vaccine and can adopt various immunization modes, can stimulate the immune response of the body in all directions, and thus has a wide development and application prospect.

The invention provides a microbial carrier vaccine, a preparation method thereof and a vaccine composition. A microbial carrier vaccine for antigen delivery with an enteric microbial delivery system is provided, and the enteric microbial delivery system is selected from at least one of a bacteriophage delivery system (e.g., Klebsiella pneumoniae bacteriophage), an Escherichia coli delivery system (e.g., Klebsiella pneumoniae bacteriophage), and an antigen delivery system (e.g., Klebsiella pneumoniae bacteriophage). Escherichia coli S17-1 lambda pi) or a conjugation delivery system of Escherichia coli and intestinal symbiotic bacteria. The microbial carrier vaccine is a vaccine platform developed based on intestinal microorganisms, after the vaccine enters a body, intestinal symbiotic bacteria can be subjected to in-situ editing, so that the intestinal symbiotic bacteria can continuously generate antigens to be applied to the body, the body can be continuously stimulated to generate antibodies, and the continuous protection effect is achieved.

The invention discloses a rabies virus glycoprotein chimeric recombinant vesicular stomatitis virus and application thereof, and belongs to the technical field of biological medicine. According to the invention, glycoproteins of two rabies viruses are assembled into the vesicular stomatitis virus vector, and the vesicular stomatitis virus recombinant rabies virus prepared from the vesicular stomatitis virus vector has high virus titer and is convenient for in-vitro culture; a vector vaccine prepared from the recombinant virus can induce animals to generate strong rabies virus neutralizing antibody response through oral immunization, and provides 100% challenge protection for the immunized animals, so that the vaccine can be used as a convenient and effective mucosal immune candidate vaccine; the vaccine has important significance on immunization of rabies virus susceptible wild animals and stray dogs and cats. The oral vaccine provided by the invention overcomes the defects of intramuscular injection vaccines, and provides a basis for the development of novel rabies virus vaccines.

The invention discloses a recombinant expression vector as well as a construction method and application thereof. The invention also discloses a recombinant strain as well as a construction method and application thereof. The invention also discloses a genetic engineering live vector vaccine. According to the invention, probiotic bacillus subtilis is used as an antigen delivery carrier, and recombinant bacillus subtilis for recombinant integration tandem expression of porcine epidemic diarrhea virus antigen neutralizing epitopes and intestinal M cell and dendritic cell (DCs) targeting peptides is constructed. The recombinant live vector vaccine is orally taken and immunized by sows, and efficient intestinal mucosa immune protection is provided for piglets in the lactation period by enhancing the intestinal mammary axial function of the sows, so that a safe, simple and convenient immune way is provided for effectively preventing the occurrence of epidemic diarrhea of the piglets.

The invention discloses an angiotensin II receptor type 1 immunogenic short peptide and application thereof. The amino acid sequence of the immunogenic short peptide is as shown in SEQ ID No.1: AFHYE. The effective component of the immunogenic vector vaccine is formed by coupling immunogenic oligopeptide and a vector. Immunogenic oligopeptides and a Qbeta carrier are coupled to obtain the vaccine effective component of the angiotensin II receptor type 1 immunogenic peptide fragment. The immunogenic carrier vaccine prepared from the active ingredients is used for antihypertensive treatment of primary hypertension, can be used as a long-acting antihypertensive drug, and is beneficial to improving the treatment compliance of patients with primary hypertension, so that the purpose of effectively controlling blood pressure is achieved.

The present application relates to a kind of recombinant adenovirus vector vaccine inhalation delivery system, the delivery system is by the modification of adenovirus vector itself and cooperate specific formulation prescription, vaccine is inhaled after inhalation administration, can reach lung by nasal cavity or oral inhalation, to generate protective immune response including mucosal immunity, while solving adenovirus pre-existing immunity, enhance the effective utilization rate of vaccine, improve the effect of vaccine.

The present invention relates to an intestinal microorganism-based composition for enhancing the efficacy of vaccinations, in particular, the persistence of antibody reactions and booster effects. The present inventors have found that specific intestinal microorganisms are significantly abundant in individuals having a long antibody half-life following vaccination with an mRNA vaccine or an adenovirus vector vaccine, or exhibiting a high immune response upon booster vaccination. Specifically, it was found that a specific microbial community including Faecalibacterium prausnitzii is associated with antibody persistence and booster response enhancement following mRNA vaccination, and Escherichia coli is associated with antibody persistence following adenovirus vector vaccination.

The present invention provides compositions and methods for immunizing a subject in need thereof again an avian pathogen. In one aspect, the invention provides a composition for immunizing an avian subject against a pathogen comprising: a) a recombinant laryngotracheitis virus vector (rLT); and b) a fusion gene of an avian virus (F) inserted into the recombinant laryngotracheitis virus vector (rLT / F); wherein the recombinant laryngotracheitis virus vector inserted with the fusion gene of the avian virus (rLT / F) is deoptimized to generate deoptimized rLT / F vaccine candidates; and wherein the deoptimized rLT / F vaccine candidates are administered to the subject in need thereof.

The application belongs to the field of biology and discloses a rabbit-derived monoclonal antibody against chicken IFN-gamma protein, which contains a heavy chain variable region and a light chain variable region; the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID No. 1; and the amino acid sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID No. 2. The rabbit-derived monoclonal antibody is named Ab-56, and has the following characteristics: 1. Compared with existing monoclonal antibodies, the rabbit-derived monoclonal antibody has strong binding capacity with interferon; 2. The rabbit-derived monoclonal antibody also has strong binding capacity with duck interferon. This provides a solid foundation for evaluation of immune protection effect of some mRNA vaccines, DNA vaccines or live virus vector vaccines and research on immune response mechanism caused by virus infection, and the rabbit-derived monoclonal antibody is not only suitable for chickens, but also suitable for ducks and even other poultry for research on vaccine evaluation and cellular immune protection mechanism. In addition, the application also provides the monoclonal antibody and application.

The application belongs to the technical field of veterinary medicine, and particularly relates to an adenovirus vector recombinant pig acute diarrhea syndrome coronavirus vaccine. The application constructs a replication-defective adenovirus vector vaccine (rAd-SADS-S) expressing a full-length SADS-CoV S protein, realizes immune induction of high-efficiency humoral and cellular immunity, and provides passive protection for milk mice through maternal antibody transmission, and overcomes the defects of no available vaccine for SADS-CoV, low protection rate in existing research, and biological safety risk.

The invention discloses a Brucella vaccine of recombinant adenovirus based on OMP31 and IFNG and application, and belongs to the technical field of biological medicine. In order to develop a safe and effective brucella recombinant adenovirus vector vaccine, a brucella immunodominance antigen is designed through a genetic engineering technology, a recombinant adenovirus of an antigen-coupled molecular adjuvant IFN-gamma is constructed, and the constructed recombinant adenovirus is identified through PCR, WB, an electron microscope and the like. And the immune stimulation capability and the protective efficacy of the brucella recombinant adenovirus vector vaccine are evaluated by verifying the cellular immune response level and the humoral immune response level induced by the vaccine at a mouse level and the challenge protection efficiency, so that a foundation is laid for research and development of a brucella recombinant adenovirus candidate vaccine.